Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
EFFECT - SenesTech, Inc. (0001680378) (Filer)
424B3 - SenesTech, Inc. (0001680378) (Filer)
S-3 - SenesTech, Inc. (0001680378) (Filer)
3 - SenesTech, Inc. (0001680378) (Issuer)
4 - SenesTech, Inc. (0001680378) (Issuer)
3 - SenesTech, Inc. (0001680378) (Issuer)
94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the second quarter ended June 30, 2025. Q2 2025 Highlights Revenues increased 36% to $625,000, a record for the Company, from $459,000 in Q2 2024.Evolve Rodent Birth Control products sales grew 94%
Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern time PHOENIX, July 31, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control for managing animal pest populations, will report second quarter 2025 financial results for the period ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company has scheduled a conference call that same day, Thursday, August 7, 2025, at 5:00 p.m. Eastern time, to review the results. Second Quarter 2025 Conference Call Details Date and Time: Th
SURPRISE, Ariz., May 8, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the first quarter ended March 31, 2024. Q1 2025 Highlights Revenues increased 17% to $485,000 from $415,000 in Q1 2024.Evolve product sales grew 40% year-over-year, now representing 79% of total revenue.Gross profit margin expanded to 64.5%, a record for the Company, compared to 32.5% in Q1 2024.Net loss for Q1 2025 was
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G/A - SenesTech, Inc. (0001680378) (Subject)
SC 13G - SenesTech, Inc. (0001680378) (Subject)
SURPRISE, Ariz., Aug. 18, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control for managing animal pest populations, today announced that it will participate in a webcast presentation at the Lytham Partners 2025 Consumer & Technology Investor Summit, taking place virtually on Tuesday, August 19, 2025. The webcast will take place at 3:30 p.m. ET on Tuesday, August 19, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/cts2025/ or directly at https://lythampartners.com/cts2025/snes. A replay will also
94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the second quarter ended June 30, 2025. Q2 2025 Highlights Revenues increased 36% to $625,000, a record for the Company, from $459,000 in Q2 2024.Evolve Rodent Birth Control products sales grew 94%
SURPRISE, Ariz., Aug. 5, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a leader in fertility control for managing animal pest populations, announced today the closing of its previously announced exercise of certain outstanding warrants to purchase an aggregate of 1,458,872 shares of the Company's common stock originally issued by the Company on July 1, 2025, at the existing exercise price of $4.15 per share. H.C. Wainwright acted as the exclusive placement agent for the transaction. As consideration for the exercise of such existing
PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye
PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.